MBMahnaz Boush

Mahnaz Boush

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahnaz Boush has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harnessing ChatGPT for Human Resource Management: Opportunities, Challenges, and Strategic Implications

    by Raha Aghaei, Ali Akbar Kiaei, Mahnaz Bush, Javad Vahidi, Zeinab Barzegar, Mohammad Zavvar, Mahan Rofoosheh

    The integration of ChatGPT and human resources management (HRMs) is changing the way organizations manage their workforces. This white paper examines the key benefits and challenges of implementing the ChatGPT in human resource management, providing a comprehensive overview of its effectiveness, integrity, and impact on decision-making. ChatGPT streamline HR processes by automating mundane tasks, reducing biases in hiring and performance appraisal, and supporting individual employee development programs. It also facilitates data-driven decision-making through predictive analytics and provides valuable insights into employee performance and engagement. However, successful adoption of an ChatGPT requires seamless integration with existing systems and ongoing learning and adaptation to address privacy and security concerns. Ethical issues, such as transparency and fairness, are crucial to building trust and ensuring the responsible use of AI. Based on real-world applications and first-time user experiences, this paper provides strategic recommendations for HR professionals and organizations to leverage ChatGPT effectively and create a more efficient, inclusive, and data-driven HR environment.


  • Open Access

    Harnessing the Potential of Large Language Models in Modern Marketing Management: Applications, Future Directions, and Strategic Recommendations

    by Raha Aghaei, Ali A. Kiaei, Mahnaz Boush, Javad Vahidi, Mohammad Zavvar, Zeynab Barzegar, Mahan Rofoosheh

    Large Language Models (LLMs) have revolutionized the process of customer engagement, campaign optimization, and content generation, in marketing management. In this paper, we explore the transformative potential of LLMs along with the current applications, future directions, and strategic recommendations for marketers. In particular, we focus on LLMs major business drivers such as personalization, real-time-interactive customer insights, and content automation, and how they enable customers and business outcomes. For instance, the ethical aspects of AI with respect to data privacy, transparency, and mitigation of bias are also covered, with the goal of promoting responsible use of the technology through best practices and the use of new technologies businesses can tap into the LLM potential, which help growth and stay one step ahead in the turmoil of digital marketing. This article is designed to give marketers the necessary guidance by using best industry practices to integrate these powerful LLMs into their marketing strategy and innovation without compromising on the ethos of their brand.


  • Open Access

    A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol

    by Sogand Sadeghi, Ali A. Kiaei, Mahnaz Boush, Nader Salari, Masoud Mohammadi, Danial Safaei, Mitra Mahboubi, Arian Tajfam, Sabra Moghadam

    Background Adenocarcinoma of the lung is the most common type of lung cancer, and it is characterized by distinct cellular and molecular features. It occurs when abnormal lung cells multiply out of control and form a tumor in the outer region of the lungs. Adenocarcinoma of the lung is a serious and life-threatening condition that requires effective and timely management to improve the survival and quality of life of the patients. One of the challenges in this cancer treatment is finding the optimal combination of drugs that can target the genes or proteins that are involved in the disease process. Method In this article, we propose a novel method to recommend combinations of trending drugs to target its associated proteins/genes, using a Graph Neural Network (GNN) under the RAIN protocol. The RAIN protocol is a three-step framework that consists of: 1) Applying graph neural networks to recommend drug combinations by passing messages between trending drugs for managing disease and genes that act as potential targets for disease; 2) Retrieving relevant articles with clinical trials that include those proposed drugs in previous step using Natural Language Processing (NLP). The search queries include “Adenocarcinoma of the lung”, “Gefitinib”, “Paclitaxel”, “Icotinib” that searched context based in databases using NLP; 3) Analyzing the network meta-analysis to measure the comparative efficacy of the drug combinations. Result We applied our method to a dataset of nodes and edges that represent the network, where each node is a drug or a gene, and each edge is a p-value between them. We found that the graph neural network recommends combining Gefitinib, Paclitaxel, and Icotinib as the most effective drug combination to target this cancer associated proteins/genes. We reviewed the clinical trials and expert opinions on these medications and found that they support our claim. The network meta-analysis also confirmed the effectiveness of these drugs on associated genes. Conclusion Our method is a novel and promising approach to recommend trending drugs combination to target cancer associated proteins/genes, using graph neural networks under the RAIN protocol. It can help clinicians and researchers to find the best treatment options for patients, and also provide insights into the underlying mechanisms of the disease. Highlights Proposing the combination of medicinal compounds together for the treatment of lung adenocarcinoma achieved a p-value of 0.002858 between lung adenocarcinoma and targeted proteins/genes 3-Leveraging GraphSAGE for Suggesting an Optimal Drug Combinations.


  • Open Access

    Graph Attention Networks for Drug Combination Discovery: Targeting Pancreatic Cancer Genes with RAIN Protocol

    by Elham Parichehreh, Ali A. Kiaei, Mahnaz Boush, Danial Safaei, Reza Bahadori, Nader Salari, Masoud Mohammadi, Alireza Khorram

    Background Malignant neoplasm of the pancreas (MNP), a highly lethal illness with bleak outlook and few therapeutic avenues, entails numerous cellular transformations. These include irregular proliferation of ductal cells, activation of stellate cells, initiation of epithelial-to-mesenchymal transition, and changes in cell shape, movement, and attachment. Discovering potent drug cocktails capable of addressing the genetic and protein factors underlying pancreatic cancer’s development is formidable due to the disease’s intricate and varied nature. Method In this study, we introduce a fresh model utilizing Graph Attention Networks (GATs) to pinpoint potential drug pairings with synergistic effects for MNP, following the RAIN protocol. This protocol comprises three primary stages: Initially, employing Graph Neural Network (GNN) to suggest drug combinations for disease management by acquiring embedding vectors of drugs and proteins from a diverse knowledge graph encompassing various biomedical data types, such as drug-protein interactions, gene expression, and drug-target interactions. Subsequently, leveraging natural language processing to gather pertinent articles from clinical trials incorporating the previously recommended drugs. Finally, conducting network meta-analysis to assess the relative effectiveness of these drug combinations. Result We implemented our approach on a network dataset featuring drugs and genes as nodes, connected by edges representing their respective p-values. Our GAT model identified Gemcitabine, Pancrelipase Amylase, and Octreotide as the optimal drug combination for targeting the human genes/proteins associated with this cancer. Subsequent scrutiny of clinical trials and literature confirmed the validity of our findings. Additionally, network meta-analysis confirmed the efficacy of these medications concerning the pertinent genes. Conclusion By employing GAT within the RAIN protocol, our approach represents a novel and efficient method for recommending prominent drug combinations to target proteins/genes associated with pancreatic cancer. This technique has the potential to aid healthcare professionals and researchers in identifying optimal treatments for patients while also unveiling underlying disease mechanisms. Highlights Graph Attention Networks (GATs) used to recommend drug combinations for pancreatic cancer RAIN protocol applied to extract relevant information from clinical trials and literature Gemcitabine, Pancrelipase Amylase, and Octreotide identified as optimal drug combination Network meta-analysis confirmed the effectiveness of the drug combination on gene targets Novel and efficient method for drug discovery and disease mechanism elucidation


  • Open Access

    FPL: False Positive Loss

    by Ali Akbar Kiaei, Mahnaz Boush, Danial Safaei, Sadegh Abadijou, Nima Baselizadeh, Ali Fayzi, Reza Bahadori, Nader Salari

    When training deep neural networks tasks, the most popular choices are cross-entropy loss. On the other hand, in general speaking, a decent loss function can take on shapes that are considerably more flexible and ought to be adapted for different activities and datasets. In most of the classification tasks, generally if the true class is not correctly recognized by the network (top1), that class is placed among the five classes with the highest probability (top5). This shows that the network does not necessarily recognize the correct class with a low probability, but a class similar to it (such as 3 vs. 8 in mnist) assigns a higher probability and this causes a mistake in that task. Accordingly, we proposed a loss function deals with the error of class that the neural network incorrectly recognized as correct, in addition to the correct class error. We call our proposed loss as False Positive Loss (FPL), with the intention of viewing and designing loss functions not only through the utilization of true class but also through the utilization of the value of false positive classes. One of the core properties of our proposed loss is full adaptability, which makes False Positive Loss be fully capable of getting reformulated by using other widely used loss functions formulas based on the task or the need of the users. Extensive experimental results demonstrate that our suggested loss function outperforms other well-known losses on a variety of tasks and datasets. As can be observed, the performance of our False Positive Loss is superior to that of the cross-entropy loss when it comes to tasks involving 2D picture classification. We have compared our loss with cross entropy as the most common classification loss function on some models (such as ResNet-18, ResNet-50 and Efficientnet-V2) through classification known as a basic computer vision task. with both random or pre-trained initial weights. As a result, in some cases the models with our loss outperform the same tasks with cross entropy from the viewpoint of some metric (i.e. accuracy and FP). For example, the resnet-50 on cifar-10 dataset with random initialization indicated a top1 accuracy of 94.93 with cross entropy and 95.25 with our loss, while for top5 accuracy the results are 99.86 and 99.87, respectively.


  • Open Access

    Diagnosing Alzheimer's Disease Levels Using Machine Learning and MRI: A Novel Approach

    by Reza Bahadori, Ali Akbar Kiaei, Hourieh Malek Zadeh, Mahnaz Boush, Sadegh Abadijou, Danial Safaei, Amir Hossein Mehdikhani

    Alzheimer's disease is a neurological illness that worsens gradually. It is known as the most frequent cause of dementia. Moreover, Alzheimer's disease is a general term for memory loss and other cognitive impairments severe enough to disrupt daily life. The disease often grows in middle-aged and elderly people with the gradual loss of cognitive ability. Since the diagnosis of the illness is time consuming, a novel machine learning approach is proposed in this research to diagnose Alzheimer's levels based on Magnetic Resonance Imaging (MRI). More specifically, to provide distinct information for classification we have implemented the proposed method on a native MRI scans dataset containing three MRI channels; namely T1, T2, and, T2 tirm, which are shown in red, blue and green, respectively. The five middle layers of these three types of MRI scans are combined to form five RGB layers. In addition, we use a Convolutional Neural Network to classify each composed layer, and the final disease type is predicted using majority voting. finally, the F1-Score has been used to assess method performance, indicated that 92% of predictions of the proposed model were accurate.


  • Open Access

    Active Identity Function as Activation Function

    by Ali Akbar Kiaei, Mahnaz Boush, Danial Safaei, Sadegh Abadijou, Nima Baselizadeh, Nader Salari, Masoud Mohammadi

    Selecting the optimal activation function for training deep neural networks has always been challenging because it significantly impacts the neural network’s performance and training speed. At this point, researchers are more likely to employ RELU than other well-known activation functions. After RELU, researchers have proposed many activation functions to improve RELU. None of them was capable of surpassing RELU as their most significant rival. SWISH outperformed RELU in several challenging experiments like classification, object detection, and tracking. Replacing RELU units with SWISH, which improves performance in many tasks. This paper proposed a new activation function surpassing Google’s brain’s SWISH function, Which we named AIF. Experiments indicate that our proposed activation function outperforms SWISH in various tasks.


  • Open Access

    Systematic review and network meta-analysis of drug combinations suggested by machine learning on genes and proteins, with the aim of improving the effectiveness of Ipilimumab in treating Melanoma

    by Danial Safaei, Ali A. Kiaei, Mahnaz Boush, Sadegh Abadijou, Alireza Khorramabadi, Nader Salari, Masoud Mohammadi, Elham Parichehreh

    Background: (Importance) One of the most dangerous kinds of skin cancer, Melanoma, develops in the cells (melanocytes) that make melanin, the pigment responsible for giving your skin its color. As well as developing everywhere on the body, including the eyes, Melanoma can sporadic occur internally, such as in the nose or throat. It is unknown what causes all melanomas, although exposure to ultraviolet (UV) radiation from the sun, tanning salons, and lamps increases the risk of getting them. As a result, radiation exposure increases the chance of obtaining Melanoma. Limiting your exposure to UV radiation can help reduce your risk of Melanoma. (Objective) Due to the unknown nature of this disease and its severe impact on human genes, the use of safe and effective drug combinations for treatment is very important. Proposed drug combinations should be administered with the greatest positive effect on the genes involved. Therefore, it is important to suggest an effective drug combination that can significantly affect the genes involved. Method: (Data sources) This systematic review and network meta-analysis searched various databases, including Science Direct, Embase, Scopus, PubMed, Web of Science (ISI), and Google Scholar, without a lower time limit and up until July 2022, for articles focused on drug combinations for managing Melanoma. The study utilized a network meta-analysis to explore the effectiveness of the proposed medication combination on genes and proteins that may act as potential targets for improving Melanoma treatment. Results: The results of this study show that the p-value between the proposed drug combination and Melanoma was 1.12E-08. This is while the p-value of Melanoma and only one drug has a maximum value of 0.0149. Therefore, the proposed drug combination’s effectiveness for treating Melanoma has increased 74 times. A systematic review has investigated the validity of the proposed drug combinations, human genes network meta-analysis, and prescription drug information. Conclusion: The findings from this systematic review and meta-analysis suggest that the proposed drug combination reduces the p-value between Melanoma and genes that could potentially be targeted to slow the progression of the disease, ultimately improving its management. Therefore, selecting the appropriate drug combination is critical for enhancing community health and reducing per capita treatment expenses. Highlights: Melanoma is one of the most aggressive kinds of skin cancer, and it begins in the cells (melanocytes) responsible for producing melanin. Therapy must make use of pharmacological combinations that are both safe and effective. Any proposed medication combinations must be delivered in a way that will have the maximum possible beneficial impact on the genes at play. In this research, an effective pharmacological combination for the treatment of melanoma illness is investigated. The results suggest that the suggested treatment combination is beneficial in the treatment of Melanoma, as it reduces the p-value between the disease and the genes identified as potential targets for therapy. This indicates that the proposed treatment approach has the potential to improve the management of Melanoma.


  • Open Access

    Recommending Drug Combinations Using Reinforcement Learning targeting Genes/proteins associated with Heterozygous Familial Hypercholesterolemia: A comprehensive Systematic Review and Net-work Meta-analysis

    by Ali A. Kiaei, Mahnaz Boush, Sadegh Abadijou, Saeb Momeni, Danial Safaei, Reza Bahadori, Nader Salari, Masoud Mohammadi

    Background: Familial Hypercholesterolemia (FH) is a genetic disorder in lipoprotein metabolism caused by mutations that increase LDL and total cholesterol levels. High LDL and cholesterol levels increase atherosclerosis risk. FH mutations impact the LDL receptor (LDLR) gene, apolipoprotein B, and PCSK9. About 20% of FH cases have a polygenic basis that affects LDL levels. We decided to conduct a systematic review of the available research in this field to provide a thorough genes/proteins network meta-analysis on the impact of drug combinations on the management of heterozygous Familial Hypercholesterolemia (HeFH). This paper reviews and analyzes the literature on the effects of medication combinations on HeFH management. This study investigates articles that analyzed the management and adjuvants of HeFH to recommend forceful drug combinations. Methods: This systematic review and network meta-analysis analyzed the Science Direct, Embase, Scopus, PubMed, Web of Science (ISI), and Google Scholar databases without a lower time limit and up to July 2022. The current study consists of three fundamental stages. Firstly, drug combinations are recommended by reinforcement learning. In the second stage, we used a systematic review to analyze RL's outcomes in diverse populations (with a variety of ages, sex, etc.). Natural Language Processing (NLP) employs context to search these articles. We contrasted manual and NLP-based searches and discovered that NLP could find articles based on MeSH, not simply words. In stage three, we analyze RL outcomes using network meta-analysis. Results: This study uses the RAIN method to investigate the most effective medication combination for managing Heterozygous Familial Hypercholesterolemia (HeFH). Results from the method indicate that the best-recommended scenario is 2.7 times more efficient than the prescription of Ezetimibe as the initial scenario. Conclusion: Our systematic review and network meta-analysis review indicate that a drug combination of Ezetimibe, Pravastatin, and Simvastatin is highly effective. However, additional high-quality clinical trials are required to determine the efficacy and safety of other treatments.


  • Open Access

    Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method

    by Aliakbar Kiaei, Nader Salari, Mahnaz Boush, Kamran Mansouri, Amin Hosseinian-Far, Hooman Ghasemi, Masoud Mohammadi

    COVID-19 affects several human genes, each with its own p-value. The combination of drugs associated with these genes with small p-values may lead to an estimation of the combined p-value between COVID-19 and some drug combinations, thereby increasing the effectiveness of these combinations in defeating the disease. Based on human genes, we introduced a new machine learning method that offers an effective drug combination with low combined p-values between them and COVID-19. This study follows an improved approach to systematic reviews, called the Systematic Review and Artificial Intelligence Network Meta-Analysis (RAIN), registered within PROSPERO (CRD42021256797), in which, the PRISMA criterion is still considered. Drugs used in the treatment of COVID-19 were searched in the databases of ScienceDirect, Web of Science (WoS), ProQuest, Embase, Medline (PubMed), and Scopus. In addition, using artificial intelligence and the measurement of the p-value between human genes affected by COVID-19 and drugs that have been suggested by clinical experts, and reported within the identified research papers, suitable drug combinations are proposed for the treatment of COVID-19. During the systematic review process, 39 studies were selected. Our analysis shows that most of the reported drugs, such as azithromycin and hydroxyl-chloroquine on their own, do not have much of an effect on the recovery of COVID-19 patients. Based on the result of the new artificial intelligence, on the other hand, at a significance level of less than 0.05, the combination of the two drugs therapeutic corticosteroid + camostat with a significance level of 0.02, remdesivir + azithromycin with a significance level of 0.03, and interleukin 1 receptor antagonist protein + camostat with a significance level 0.02 are considered far more effective for the treatment of COVID-19 and are therefore recommended. Additionally, at a significance level of less than 0.01, the combination of interleukin 1 receptor antagonist protein + camostat + azithromycin + tocilizumab + oseltamivir with a significance level of 0.006, and the combination of interleukin 1 receptor antagonist protein + camostat + chloroquine + favipiravir + tocilizumab7 with corticosteroid + camostat + oseltamivir + remdesivir + tocilizumab at a significant level of 0.009 are effective in the treatment of patients with COVID-19 and are also recommended. The results of this study provide sets of effective drug combinations for the treatment of patients with COVID-19. In addition, the new artificial intelligence used in the RAIN method could provide a forward-looking approach to clinical trial studies, which could also be used effectively in the treatment of diseases such as cancer.